title: Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.
abstract: Prostacyclin (PGI(2)) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI(2) also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI(2) analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI(2) can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.
authors.affiliation: Department of Thoracic Oncosurgery, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. wangjshxjtu@gmail.com
authors.forename: Jiansheng
authors.initials: J
authors.lastname: Wang
authors.forename: Jia
authors.initials: J
authors.lastname: Zhang
authors.forename: Junping
authors.initials: J
authors.lastname: Sun
authors.forename: Jiangli
authors.initials: J
authors.lastname: Han
authors.forename: Yutao
authors.initials: Y
authors.lastname: Xi
authors.forename: Geru
authors.initials: G
authors.lastname: Wu
authors.forename: Kristina X
authors.initials: KX
authors.lastname: Duan
authors.forename: Mingxin
authors.initials: M
authors.lastname: Zhang
authors.forename: Suna
authors.initials: S
authors.lastname: Zhou
authors.forename: Qi
authors.initials: Q
authors.lastname: Liu
mesh_terms: D000792:Angiography / Q000379:methods; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000379:methods; D011464:Epoprostenol / Q000008:administration & dosage*; D006801:Humans; D016285:Iloprost / Q000494:pharmacology; D051379:Mice; D032383:Myocytes, Cardiac / Q000166:cytology; D009369:Neoplasms / Q000188:drug therapy*; D018384:Oxidative Stress; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D004317:Doxorubicin; D011464:Epoprostenol; D016285:Iloprost